Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2001, p. 1450-1455, Vol. 45, No. 5
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.5.1450-1455.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inhibition of Intramacrophage Growth of
Penicillium marneffei by 4-Aminoquinolines
Donatella
Taramelli,1,*
Clara
Tognazioli,1
F.
Ravagnani,2
O.
Leopardi,3
G.
Giannulis,3 and
J. R.
Boelaert4
Istituto di Microbiologia, Universita di
Milano,1 and Division of Blood
Transfusion, National Cancer Institute,2 Milan,
and Institute of Pathology, ASL Lodi,3
Italy, and Division of Renal and Infectious Diseases,
Algemeen Ziekenhuis Sint Jan, Bruges, Belgium4
Received 25 May 2000/Returned for modification 17 July
2000/Accepted 30 January 2001
 |
ABSTRACT |
The antimicrobial activities of chloroquine (CQ) and several
4-aminoquinoline drugs were tested against Penicillium
marneffei, an opportunistic fungus that invades and grows inside
macrophages and causes disseminated infection in AIDS patients. Human
THP1 and mouse J774 macrophages were infected in vitro with P. marneffei conidia and treated with different doses of drugs for
24 to 48 h followed by cell lysis and the counting of P. marneffei CFU. CQ and amodiaquine exerted a dose-dependent
inhibition of fungal growth, whereas quinine and artemisinin were
fungistatic and not fungicidal. The antifungal activity of CQ was not
due to an impairment of fungal iron acquisition in that it was not
reversed by the addition of iron nitrilotriacetate, FeCl3,
or iron ammonium citrate. Perl's staining indicated that CQ did not
alter the ability of J774 cells to acquire iron from the medium. Most
likely, CQ's antifungal activity is due to an increase in the
intravacuolar pH and a disruption of pH-dependent metabolic processes.
Indeed, we demonstrate that (i) bafilomycin A1 and ammonium chloride, two agents known to alkalinize intracellular vesicles by different mechanisms, were inhibitory as well and (ii) a newly synthesized 4-amino-7-chloroquinoline molecule (compound 9), lacking the terminal amino side chain of CQ that assists in drug accumulation, did not
inhibit P. marneffei growth. These results suggest that CQ has a potential for use in prophylaxis of P. marneffei
infections in human immunodeficiency virus-infected patients in
countries where P. marneffei is endemic.
 |
INTRODUCTION |
Chloroquine (CQ) is a widely
available and inexpensive drug belonging to the family of
7-chloro-4-aminoquinoline compounds (22). It is currently
employed for malaria prophylaxis and therapy; its hydroxy derivative is
also used as an anti-inflammatory agent in the treatment of rheumatoid
arthritis and systemic lupus erythematosus. Depending on the chemical
characteristics and the length of the side chain in position 4, the
aminoquinolines are monoprotic or diprotic weak bases: they diffuse
freely in the membranes in the unprotonated form, but once they reach
an intracellular acidic environment, they rapidly become protonated and
accumulate, raising the intravacuolar pH (9, 16). Hence,
these molecules can alter the activity of the acidic vesicle system
that in mammalian cells includes the endosomes, the lysosomes, the
Golgi complex, and, in the case of several types of intracellular
pathogens, the phagosomes and phagolysosomes. The activity of CQ
against intraerythrocytic Plasmodium spp. is accomplished by
its accumulation via pH trapping in the acidic food vacuole of the
parasites; binding to a specific substrate, heme, derived from the
proteolysis of host hemoglobin; and finally, inhibition of heme
detoxification (4, 10, 16, 20). Alkalization of the
endosome and/or phagolysosome seems to explain the antimicrobial
activity of CQ against several intracellular microorganisms, such as
Histoplasma capsulatum (21), Cryptococcus
neoformans (18, 19), Legionella pneumophila (6), and Francisella
tularensis (12).
These antimicrobial properties prompted us to investigate the potential
inhibitory effects of CQ and several quinoline derivatives on
Penicillium marneffei, an opportunistic pathogen endemic in Southeast Asia that causes disseminated infection in AIDS patients (8, 26, 27). P. marneffei is dimorphic: it
grows at 25°C as a mold and at 37°C as a yeast. In vivo, it invades
the cells of the mononuclear phagocyte system where it divides by
fission as a yeast (7, 8). An in vitro macrophage model
that allows evaluation of the extent of intracellular P. marneffei growth was developed. It was demonstrated that the
activation of J774 murine macrophages or human THP1 cells by treatment
with lipopolysaccharide (LPS) plus gamma interferon (IFN-
) reduces
the recovery of live fungi via nitric oxide-dependent and -independent
mechanisms (28). This system was used in the present study
to assess the potential activity of CQ against P. marneffei
and to study its mechanism of action.
 |
MATERIALS AND METHODS |
Mice.
Pathogen-free female CD1 mice, 6 to 8 weeks old, were
obtained from Charles River Italia (Calco, Como, Italy) and were
housed, fed, and handled in compliance with prescriptions for the care and use of laboratory animals.
Reagents.
Ferric ammonium citrate, FeCl3
· 6H2O, iron nitriloacetate (FeNTA), CQ, amodiaquine
(AM), and quinine were from Sigma Italia (Milan, Italy). Artemisinin
was a kind gift from R. Carter, Knoll, Switzerland. The
4-aminoquinoline derivatives used in this study (compounds 9 and 15)
(Fig. 1) were a kind gift of Timothy J. Egan, Department of Chemistry, University of Cape Town, Cape Town,
South Africa. They were synthesized from 4-chloroquinoline as
previously described (10).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Structure and numbering of CQ and AM (a) and the
4-aminoquinoline compounds used in this study (b) and their pK values
(c) (10, 15; T. J. Egan, personal communication).
|
|
Strain.
The strain of P. marneffei used in this
study, IUM 885346, was kindly provided by M. A. Viviani. It was
isolated from the blood of a human immunodeficiency virus
(HIV)-positive Italian male intravenous drug user who had been infected
in Thailand (7). The fungus was cultured on yeast
morphology agar (YMA) (Biolife, Milan, Italy) at 25°C for 10 to 14 days. Conidia were then collected by flooding the culture surface with
saline, centrifuged at 4,000 × g for 20 min, and
filtered to remove mixed mycelial debris, as previously described
(28).
Macrophage cell lines.
The murine macrophage-like cell line
J774 was maintained in minimal essential medium (MEM) (GIBCO BRL)
supplemented with 10% heat-inactivated fetal bovine serum (Euroclone,
Ltd.), 1% glutamine, 2% HEPES buffer, 1% penicillin-streptomycin
(Biological Ind., Kibbutz, Israel), and 1% nonessential amino acids
(complete medium) (GIBCO BRL) in 5% CO2 at 37°C in petri
dishes (Cellstar; Greiner, Ltd., Kremsmuster, Austria). J774
macrophages were mechanically collected with a cell lifter (Costar
Italia, Milan, Italy) and transferred to fresh medium every 3 to 4 days. Human THP1 cells were grown in suspension in complete RPMI 1640 medium (GIBCO BRL). They were differentiated by treatment with 0.32 µM phorbol myristate acetate (PMA) for 72 h (28).
Assay of antifungal activity of macrophages.
PMA-differentiated THP1 cells or J774 macrophages were seeded in
triplicate in 24-well Costar plates at 105 cells/well in
complete medium and incubated at 37°C in 5% CO2 for
24 h; confluent monolayers were then treated with P. marneffei conidia (2 × 105/well) for 2 h of
phagocytosis in the absence of opsonins. Since the microscopic count of
conidia cannot distinguish viable from dead fungi, the number of CFU at
72 h did not always match the number of conidia of the initial
inoculum but varied depending on conidium viability. We did not include
experiments in which the viability of conidia was below 60%. After
phagocytosis, cell monolayers were washed with warm phosphate-buffered
saline to remove nonphagocytized conidia, and either lysed, treated
with different concentrations of drugs, or stimulated with 100 U of recombinant IFN-
(Genzyme)/ml and 1 µg of LPS (from E. coli O111:B4; Sigma)/ml in complete medium, as previously
described (28). The number of CFU recovered from the lysis
of J774 or THP1 cells after 2 h of phagocytosis was considered the
initial inoculum and indicated as the "baseline" value in all
figures and the table. At the end of 24 or 48 h of incubation,
macrophages were lysed with 0.1% Tween 20 in saline and the
phagocytized yeasts were recovered, centrifuged, and plated in serial
dilution in triplicate in YMA for 72 h at 25°C. The results are
expressed as mean CFU ± standard errors of the mean (SEM) from
three or four different experiments.
The degree of iron loading was evaluated histochemically. J774
macrophages were seeded into chamber slides (Nunc) at 5 × 105 cells/well in complete medium and treated with 250 µM
FeCl3 plus 10 µM CQ or FeCl3 alone for
48 h. At the end of the incubation, slides were rinsed with
saline, fixed in 4% buffered formalin, and then stained with Prussian
blue according to the method of Perl (23).
Cell viability.
The MTT [3-(4,5
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (M-2128; Sigma)
assay was used to determine the viability of J774 macrophages after
treatment with antimalarial drugs (29). Briefly,
105 J774 cells were seeded in quadruplicate in 96-well
plates in complete medium and serial dilutions of the drugs. The plates were incubated for 48 h at 37°C in 5% CO2; then, 20 µl
of a 5-mg/ml solution of MTT in phosphate-buffered saline was added,
and incubation continued for an additional 3 h at 37°C. The
plates were then centrifuged, the supernatants were discarded, and the
dark blue formazan crystals were dissolved using 100 µl of lysing
buffer consisting of a solution of 20% (wt/vol) sodium dodecyl sulfate (Sigma) and 40% N,N-dimethylformamide (Merck) in
H2O at pH 4.7 adjusted with 80% acetic acid. The plates
were then read on a microplate reader (Molecular Devices Co., Menlo
Park, Calif.) using a test wavelength of 550 nm and a reference
wavelength of 650 nm. The optical density at 650 nm (OD650)
was subtracted from the OD550 to eliminate nonspecific
background. A similar method was employed to measure the effects of
antimalarial drugs on P. marneffei cultured in 96-well
plates for 72 h, as described previously (17).
 |
RESULTS |
Effects of CQ and other antimalarial compounds on P. marneffei growth in human and mouse macrophages.
P.
marneffei multiplies inside murine J774 cells, as evidenced by an
approximately twofold increase in CFU after 48 h of culture (Fig.
2A). Treatment of J774 cells with CQ at
2 h postinfection induced a significant and dose-dependent
inhibition of P. marneffei growth (Fig. 2A and B). CQ was
fungistatic at 5 µM and fungicidal at 10 µM. The antifungal
activity of CQ was comparable to that obtained by the activation of
cells with IFN-
plus LPS (Fig. 2A and reference 28).
Similar results were obtained using the human monocyte/macrophage cell
line THP1 (Fig. 2C) or fresh peritoneal macrophages from CD1 mice (data
not shown).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Inhibition of intracellular P. marneffei
growth by CQ. (A) Antifungal activity of J774 macrophages treated with
10 µM CQ or stimulated with IFN- plus LPS. The data are expressed
as mean CFU ± SEM recovered from triplicate cultures of a
representative of three experiments. (B) Dose-dependent effect of CQ
against P. marneffei conidia phagocytized by J774
macrophages for 2 h. The data are expressed as mean CFU ± SEM recovered from three different experiments in triplicate. (C)
Dose-dependent effect of CQ against P. marneffei conidia
phagocytized by PMA-differentiated human THP1 cells for 2 h. The
data are expressed as mean CFU ± SEM recovered from three
different experiments in triplicate.
|
|
In addition to CQ, several other antimalarials were assayed for
anti-P. marneffei activity in J774 cells. Table
1 shows that CQ and AM, both
4-aminoquinoline drugs, but not primaquine, an 8-aminoquinoline, all
tested at 10 µM, were active in reducing P. marneffei
survival. The effect was significant at 24 h and even more
marked at 48 h. Between 24 and 48 h, the intracellular multiplication of P. marneffei was completely inhibited in
the CQ- and AM-treated cells, whereas a 2.4-fold increase in CFU was seen in control groups. In contrast, quinine and artemisinin exerted fungistatic effects that were mostly prominent after 48 h. As measured by the MTT assay, none of the drugs employed was toxic for
J774 macrophages (Table 1, last column).
Effect of exogenous iron supplementation.
Since some of the
antimicrobial effects of CQ have been attributed to its ability to
restrict iron availability to intracellular pathogens (6, 12,
21), the activity of CQ was examined in the presence of
exogenous iron supplementation. The addition of FeNTA, ferric ammonium
citrate, or ferric chloride did not modify the antifungal activity of
CQ at 10 µM against P. marneffei (Fig.
3). To ascertain whether CQ could impair
cellular accumulation of exogenous iron by interfering with the
endocytic pathway, J774 cells were examined by Perl's staining after
incubation with 250 µM ferric chloride. The positive stain of
CQ-treated and control J774 cells demonstrates that cellular iron
loading was not affected by treatment with 10 µM CQ. It is therefore
unlikely that CQ exerts its anti-P. marneffei activity by
impairing the acquisition of iron by the fungus.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of exogenous iron supplementation on the activity
of CQ against intracellular growth of P. marneffei. P. marneffei conidia were incubated with J774 cells for 2 h at a
2:1 ratio in triplicate. After removal of nonphagocytized conidia,
cultures were treated with CQ in the presence of FeNTA (50 µg/ml),
FeCl3 (250 µM), or ferric NH4 citrate (100 µg/ml) and incubated for a further 48 h. The data are expressed
as mean CFU ± SEM recovered from triplicate cultures of a
representative of three experiments.
|
|
Effects of vacuolar pH-neutralizing agents on P. marneffei survival.
To investigate whether the activity of
CQ was related to its ability to increase vesicular pH, both a
structurally unrelated weak base (ammonium chloride) and an inhibitor
of vacuolar H+-ATPase (bafilomycin A1) (5, 13)
were used. Both compounds increased the antifungal activity of J774
(Fig. 4A) and THP1 (data not shown)
macrophages in a concentration-dependent manner, suggesting that a pH
increase within the P. marneffei-containing phagosome may
explain the antifungal activity of CQ. Testing of compounds 9 and 15, two newly synthesized 4-aminoquinolines with different side chains and
base properties (10), further supported this hypothesis.
The structures of compound 9, a 4-amino-7-chloroquinoline, and compound
15, an N-(7-chloro-4 quinolinyl)-1,2-ethanediamine, are
shown in Fig. 1 together with those of CQ and AM, as well as the pK
values of the studied aminoquinolines. Compound 9 lacks the terminal
amino side chain of CQ that assists in drug accumulation in the acidic
compartments of macrophages via pH trapping, whereas compound 15 is
more similar to CQ. However, compounds 9 and 15 are both less
lipophilic than CQ. When assayed on J774 macrophages, compound 9, even
at 20 µM, was completely inactive against P. marneffei
(Fig. 4B), whereas compound 15 at 10 µM inhibited P. marneffei growth by 50%.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of vacuolar pH-neutralizing agents on P. marneffei growth inside J774 macrophages. (A) Inhibition of
P. marneffei growth by treatment with bafilomycin A1 and
ammonium chloride. The data are expressed as mean CFU ± SEM
recovered from triplicate cultures of a representative of three
experiments. (B) Inhibition of P. marneffei growth by
treatment with CQ, compound 15 (Cp 15), or compound 9 (Cp 9). The data
are expressed as mean CFU ± SEM recovered from triplicate
cultures of a representative of three experiments.
|
|
Effects of antimalarial compounds on P. marneffei
growth in axenic medium.
The aminoquinoline compounds were also
tested against P. marneffei conidia in a cell-free system
using MEM and the MTT assay to measure fungal viability (17,
28). None of the drugs showed any direct activity against
P. marneffei at the concentrations used in the J774 assay
(10 µM). Higher concentrations (50 µM) of CQ and AM were required
to inhibit the fungus by 75 and 86%, respectively. Treatment with 50 µM concentrations of compounds 9 and 15 resulted in a similar degree
of inhibition of P. marneffei growth (69 and 66%, respectively).
 |
DISCUSSION |
P. marneffei is assumed to enter the human body by the
respiratory route in the conidial form. It is then internalized by macrophages, where it transforms and takes a yeast-like morphology (8). It was previously reported that the same
conidium-to-yeast transition could be elicited in vitro following
phagocytosis of P. marneffei conidia by J774 macrophages and
incubation at 37°C (7). Intracellular fungus
multiplication is also documented, as measured by the two- to threefold
increase in CFU found after 48 h of culture compared to the amount
of phagocytized conidia (reference 28 and this paper). The
murine J774 cell line as well as its human promonocytic counterpart
THP1 were utilized in the present study to evaluate the effects of CQ
on the survival of P. marneffei within its macrophage habitat.
CQ inhibited intracellular P. marneffei growth in a
dose-dependent manner in both the murine and the human cell lines, as well as in primary murine macrophages. This drug has previously been
shown to exert in vitro and in vivo inhibitory effects on the growth of
two other yeasts: H. capsulatum (21) and
C. neoformans (18, 19). The beneficial effects
of CQ have been attributed to different mechanisms. In the case of
H. capsulatum, CQ impedes the pH-dependent acquisition of
iron either from the transferrin-transferrin receptor complex in the
endosome or from ferritin in the lysosome (21). By
contrast, CQ inhibits C. neoformans growth by a mechanism that is independent of iron acquisition but is related to other consequences of the pH increase in the subcellular acidic compartments (18, 19). Concerning P. marneffei, it is
unlikely that iron acquisition fully explains the inhibitory effects of
CQ, as the addition of either FeNTA, ferric chloride, or ferric
ammonium citrate did not abrogate the CQ-induced inhibition.
On the other hand, the following three arguments lend support to the
concept that CQ, which is well recognized to increase vacuolar pH,
exerts its anti-P. marneffei activity by some other pH-dependent mechanisms. First, it has previously been shown that the
fungus, when cultured axenically, grows better at an acidic pH than at
a neutral or basic pH (7). Second, CQ's effects can be
mimicked by the use of compounds that increase vacuolar pH by different
means, such as ammonium chloride, a totally unrelated molecule that
also acts as a weak base, or bafilomycin A1, which inhibits the
vacuolar proton-ATPase and hence vacuolar acidification (5,
13). Third, comparing the anti-P. marneffei activity of several quinoline derivatives yields interesting results. Indeed, the 4-aminoquinolines used, CQ and AM, share a similar inhibitory effect toward P. marneffei, whereas quinine and primaquine
are less active. This may be explained by different pKa
values of the corresponding drugs, resulting in a much higher
accumulation rate for CQ and AM than for quinine and primaquine within
the cells' acidic compartments (11, 22). AM, even if it
has slightly lower pKa values than CQ (Fig. 1), accumulates
more in vesicles for reasons unrelated to ion trapping (11,
22) which may explain its high anti-P. marneffei
activity compared to CQ. The pK1 value of primaquine is 3.2 (15), resulting in a much lower vesicular accumulation, in
agreement with its very limited anti-P. marneffei activity.
Similarly, the low pKa1 value of quinine may
explain its modest effect. Furthermore, we tested compound 9, which
differs from CQ only by the absence of the terminal amino side chain
and is therefore a much weaker base than CQ (Fig. 1) (reference
10, no precise pKa values reported; T. J. Egan personal communication). Accordingly, compound 9 has lost the
anti-P. marneffei activity of its parent, CQ. In contrast,
compound 15, in which the amino side chain is maintained, yielded
anti-P. marneffei activity. These results provide strong
support for the idea that CQ's inhibitory activity toward P. marneffei is related to the high rate of accumulation of the
diprotic drug within the P. marneffei-containing
phagolysosome and possibly in the acidic vacuole of P. marneffei itself. Very high concentrations of CQ at this specific
site may result in a direct anti-P. marneffei activity.
Indeed, when studied in a cell-free medium, CQ kills P. marneffei at concentrations 4 to 5 times higher than those needed
inside macrophages. Similarly, CQ seems to directly affect the growth
of C. neoformans (14).
The increase in pH within the phagocytic vacuole may have the following
consequences. First, the increase in intravacuolar pH may directly
reduce fungus growth (7). Second, it may inhibit pH-dependent yeast virulence factors. Both P. marneffei
mycelia and yeast from different strains have recently been reported to express acid phosphatase activity (30), considered one of
the virulence factors for intracellular pathogens such as F. tularensis (24) or Coxiella burnetii
(1). Acid phosphatases, whose optimal pH is 5, seem to
improve the survival of intracellular microorganisms by inhibiting the
respiratory burst of phagocytic cells (24).
What may be the clinical relevance of the observed in vitro inhibitory
effect of CQ toward P. marneffei? This fungus is endemic in
Southeast Asia, where HIV type 1 (HIV-1) and malaria are also highly
prevalent. In view of the fact that P. marneffei results in
clinical infection when cellular immunity is devastated to a great
extent, it is not astonishing that P. marneffei is the third
most common AIDS-related opportunistic infection in Thailand (8,
27). It is unlikely that CQ will be of use in the treatment of
established P. marneffei infections, as itraconazole, with a
MIC of 0.009 µg/ml, is clearly effective (26, 27).
However, CQ may possibly be of value in the primary prophylaxis of
P. marneffei infection in HIV-1-infected individuals living
in countries where it is endemic. Its low cost, established anti-HIV-1
effects (3, 25), and large spectrum of activity, which
encompasses several other AIDS-opportunistic pathogens
(2), are important characteristics of the drug in this setting.
 |
ACKNOWLEDGMENTS |
We thank T. J. Egan and C. H. Kaschula, from the
Department of Chemistry, University of Cape Town, Cape Town, South
Africa, and D. Monti and E. Pasini, from the Department of Organic and Industrial Chemistry, University of Milan, Milan, Italy, for
synthesizing compounds 9 and 15 and for helpful discussion throughout
this work.
This work was supported by the I.S.S., National Program for Research on
AIDS, contract no. 50B.037 and 50C.030, Rome, Italy.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Microbiologia, Universita di Milano, Via Pascal 36, 20133 Milano,
Italy. Phone: 39 02 26601 221. Fax: 39 02 26601 218. E-mail:
Donatella.Taramelli{at}unimi.it.
 |
REFERENCES |
| 1.
|
Baca, O. G.,
M. J. Roman,
R. H. Glew,
R. F. Christner,
J. E. Buhler, and A. S. Aragon.
1993.
Acid phosphatase activity in Coxiella burnetii: a possible virulence factor.
Infect. Immun.
61:4232-4239[Abstract/Free Full Text].
|
| 2.
|
Boelaert, J. R.,
R. Appelberg,
M. S. Gomes,
E. Blasi,
R. Mazzolla,
J. Grosset,
N. Lounis,
K. Soteriadou,
M. Thiakaki,
D. Taramelli, and C. Tognazioli.
2001.
Experimental results on chloroquine and AIDS-opportunists.
J. Acquir. Immune Defic. Syndr.
26:300-301.
|
| 3.
|
Boelaert, J. R.,
K. Sperber, and J. Piette.
1999.
Chloroquine exerts an additive in vitro effect when associated with didanosine and hydroxyurea.
AIDS Res. Hum. Retrovir.
15:1241-1247[CrossRef][Medline].
|
| 4.
|
Bray, P.,
O. Janneth,
K. Raynes,
M. Mungthin,
H. Ginsburg, and S. Ward.
1999.
Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum.
J. Cell Biol.
145:363-376[Abstract/Free Full Text].
|
| 5.
|
Buchmüller-Rouiller, Y.,
S. B. Corradin,
J. Smith, and J. Mauël.
1994.
Effect of increasing intravesicular pH on nitrite production and leishmanicidal activity of activated macrophages.
Biochem. J.
301:243-247.
|
| 6.
|
Byrd, T. F., and M. A. Horwitz.
1991.
Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens.
J. Clin. Investig.
88:351-357.
|
| 7.
|
Cogliati, M.,
A. Roverselli,
J. R. Boelaert,
D. Taramelli,
L. Lombardi, and M. A. Viviani.
1997.
Development of an in vitro macrophage system to assess Penicillium marneffei growth and susceptibility to nitric oxide.
Infect. Immun.
65:279-284[Abstract].
|
| 8.
|
Cooper, C. R., Jr.
1998.
From bamboo rats to humans: the odyssey of Penicillium marneffei.
ASM News
64:390-397.
|
| 9.
|
De Duve, C.,
T. De Barsy,
T. Poole,
A. Trouet,
P. Tulkens, and F. Van Hoof.
1974.
Lysosomotropic agents.
Biochem. Pharmacol.
23:2495-2531[CrossRef][Medline].
|
| 10.
|
Egan, T. J.,
R. Hunter,
C. H. Kaschula,
H. M. Marques,
A. Misplon, and J. Walden.
1999.
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, and antiplasmodial activity.
J. Med. Chem.
43:283-291
|
| 11.
|
Foley, M., and L. Tilley.
1998.
Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents.
Pharmacol. Ther.
79:55-87[CrossRef][Medline].
|
| 12.
|
Fortier, A. H.,
D. A. Leiby,
R. B. Naranayan,
E. Asafoadjei,
R. M. Crawford,
C. A. Nacy, and M. S. Meltzer.
1995.
Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth.
Infect. Immun.
63:1478-1483[Abstract].
|
| 13.
|
Gagliardi, S.,
M. Rees, and C. Farina.
1999.
Chemistry and structure activity relationships of bafilomycin A1, a potent and selective inhibitor of the vacuolar H+-ATPase.
Curr. Med. Chem.
6:1197-1212[Medline].
|
| 14.
|
Harrison, T. S.,
G. E. Griffin, and S. M. Levitz.
2000.
Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans.
J. Infect. Dis.
182:283-289[CrossRef][Medline].
|
| 15.
|
Hufford, C. D., and J. D. McChesney.
1983.
Assignments of dissociation constants of primaquine by 13C-NMR spectroscopy.
J. Heterocycl. Chem.
20:273-275.
|
| 16.
|
Krogstad, G. J., and P. H. Schlesinger.
1987.
Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum.
N. Engl. J. Med.
317:542-549[Medline].
|
| 17.
|
Levitz, S. M., and R. D. Diamond.
1985.
A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT.
J. Infect. Dis.
152:938-945[Medline].
|
| 18.
|
Levitz, S. M.,
T. S. Harrison,
A. Tabuni, and X. Liu.
1997.
Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.
J. Clin. Investig.
100:1640-1646[Medline].
|
| 19.
|
Mazzolla, R.,
R. Barluzzi,
A. Brozzetti,
J. R. Boelaert,
T. Luna,
S. Saleppico,
F. Bistoni, and E. Blasi.
1997.
Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis.
Antimicrob. Agents Chemother.
41:802-807[Abstract].
|
| 20.
|
Mungthin, M.,
P. G. Bray,
R. G. Ridley, and S. A. Ward.
1998.
Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols.
Antimicrob. Agents Chemother.
42:2973-2977[Abstract/Free Full Text].
|
| 21.
|
Newman, S. L.,
L. Gootee,
G. Brunner, and G. S. Deepe.
1994.
Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis.
J. Clin. Investig.
93:1422-1429.
|
| 22.
|
O'Neill, P. M.,
P. G. Bray,
S. R. Hawley,
S. A. Ward, and B. K. Park.
1998.
4-Aminoquinolines past, present, and future: a chemical perspective.
Pharmacol. Ther.
77:29-58[CrossRef][Medline].
|
| 23.
|
Pearse, A. G. E.
1961.
Histochemistry, 2nd ed., p. 998-1002.
Little, Brown, Boston, Mass.
|
| 24.
|
Reilly, T. J.,
G. S. Baron,
F. E. Nano, and M. S. Kuhlenschmidt.
1995.
Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis.
J. Biol. Chem.
271:10973-10983[Abstract/Free Full Text].
|
| 25.
|
Sperber, K.,
T. H. Kalb,
V. J. Stecher,
R. Banerjee, and L. Mayer.
1993.
Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes.
AIDS Res. Hum. Retrovir.
9:91-98[Medline].
|
| 26.
|
Supparatpinyo, K.,
K. E. Nelson,
W. G. Merz,
B. J. Breslin,
C. R. Cooper, Jr.,
C. Kamwan, and T. Sirisanthana.
1993.
Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.
Antimicrob. Agents Chemother.
37:2407-2411[Abstract/Free Full Text].
|
| 27.
|
Supparatpinyo, K.,
C. Khamwan,
V. Baosoung,
K. E. Nelson, and T. Sirisanthana.
1994.
Disseminated Penicillium marneffei infection in Southeast Asia.
Lancet
344:110-113[CrossRef][Medline].
|
| 28.
|
Taramelli, D.,
S. Brambilla,
G. Sala,
A. Bruccoleri,
C. Tognazioli,
L. Riviera-Uzielli, and J. R. Boelaert.
2000.
Effects of iron on extracellular and intracellular growth of Penicillium marneffei.
Infect. Immun.
68:1724-1726[Abstract/Free Full Text].
|
| 29.
|
Twentyman, P. M., and M. Luscombe.
1987.
A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.
Br. J. Cancer
56:2279-2285.
|
| 30.
|
Youngchim, S.,
N. Vanittanakom, and A. J. Hamilton.
1999.
Analysis of the enzymatic activity of mycelial and yeast phases of Penicillium marneffei.
Med. Mycol.
37:445-450[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, May 2001, p. 1450-1455, Vol. 45, No. 5
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.5.1450-1455.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vanittanakom, N., Cooper, C. R. Jr., Fisher, M. C., Sirisanthana, T.
(2006). Penicillium marneffei Infection and Recent Advances in the Epidemiology and Molecular Biology Aspects. Clin. Microbiol. Rev.
19: 95-110
[Abstract]
[Full Text]